Breast Cancer Clinical Trial
Official title:
Impact of Breast-Conserving Therapy (BCT) on Recurrence in Patients With Triple-Negative Breast Cancer (TNBC) Compared With Mastectomy
NCT number | NCT02464774 |
Other study ID # | 2014-FXY-093 |
Secondary ID | |
Status | Not yet recruiting |
Phase | N/A |
First received | June 1, 2015 |
Last updated | June 3, 2015 |
Start date | July 2015 |
Verified date | June 2015 |
Source | Sun Yat-sen University |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Food and Drug Administration |
Study type | Interventional |
RATIONALE: Triple-negative breast cancer (TNBC) is an aggressive subtype shown to have a
high risk of locoregional recurrence (LRR) and distant metastasis (DM). The equivalent
impact of breast-conserving therapy (BCT) and mastectomy on disease-free survival in
patients with early breast cancer has been established by a number of large randomized
controlled trials and meta-analysis. However, ongoing dispute exists on whether TNBC is a
good candidate for BCT.
PURPOSE: This prospective, randomized, open, single-center Phase III clinical study is
conducted to compare efficacy and safety of breast-conserving therapy and mastectomy in
treating Chinese patients with early TNBC.
Status | Not yet recruiting |
Enrollment | 464 |
Est. completion date | |
Est. primary completion date | December 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Female aged 18 - 65 years old; 2. Staging of Cancer: cT1-2N0-1M0; 3. Histological confirmed with unilateral invasive carcinoma (all pathological types are applicable); 4. Definite reports on ER/PR/Her2 receptor showing all ER/PR/Her2 negative (specific definitions: immunohistochemical detection of ER <10% tumor cells is defined as ER negative, PR <10% positive tumor cells is defined as PR-negative, Her2 is 0~1+ or 2+ but determined negative via FISH or CISH detected (no amplification) is defined as Her2 negative); 5. Newly diagnosed conditions allowing direct surgery without any absolute contraindication for surgery; 6. ECOG performance score is 0 or 1; 7. No mass or microscopic tumor residue after surgery resection; 8. Informed consent form signed. 9. Willing to return to enrolling institution for follow-up during the Active Monitoring Phase (the active treatment and observation portions) of the study. Exclusion Criteria: 1. Bilateral breast cancer; 2. Clinical or radiographic evidence of metastatic disease; 3. Widespread disease that cannot be incorporated by local excision through a single incision that achieves negative margins with a satisfactory cosmetic result; 4. Diffuse suspicious or malignant-appearing microcalcifications; 5. Positive pathologic margin; 6. Any of ER, PR or Her2 is positive; 7. Previous neoadjuvant therapy, including chemotherapy, radiotherapy and hormone therapy; 8. Prior history of breast cancer or any other malignant disease (except for basal cell carcinoma and cervical carcinoma in situ); 9. Severe systemic disease and/or uncontrollable infection, unable to be enrolled in this study; 10. Known allergic to taxane and anthracycline agents; 11. Pregnant and breast-feeding women; 12. With mental illness and cognitive impairment, unable to understand trial protocol and side effects and complete trial protocol and follow-ups; 13. Without personal freedom and independent civil capacity. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Xiaoming Xie |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease-free survival(DFS) | DFS is defined as time (measured in months) from initial local-regional surgical treatment until first recurrence (local or distant) or last follow-up. | Up to 5 years post-treatment | No |
Secondary | Locoregional recurrence-free survival(LRRFS) | LRR refers to any progression in the breast/chest wall and/or regional lymph nodes. | Up to 5 years post-treatment | Yes |
Secondary | Distant metastasis (DM) | DM is determined by clinical and radiographic means and/or histologically proven larger than 0.2mm. | Up to 5 years post-treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |